FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer By Ogkologos - July 4, 2025 438 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Olaparib June 27, 2022 GD2-CART01 May Induce Sustained Antitumour Effect in a Proportion of Patients... April 13, 2023 Understanding Serving Sizes January 15, 2021 FDA Approves Toripalimab-tpzi for Nasopharyngeal Carcinoma November 13, 2023 Load more HOT NEWS A new approach to cancer immunotherapy African American Men More Likely to Die from Low-Grade Prostate Cancer Cell Phone Use May Increase Risk of Breast and Thyroid Cancer,... How to Keep Your Loved One With Cancer Safe From Infection...
